Atrium Therapeutics, Inc. (RNA) Earnings History
Net Loss8 years of earnings data (2018–2025) · Currently unprofitable on a TTM basis
Loading earnings history...
Atrium Therapeutics, Inc. (RNA) Earnings Overview
As of June 16, 2026, Atrium Therapeutics, Inc. (RNA) reported trailing twelve-month net income of -$396M, reflecting -55.0% year-over-year growth. The company earned $-23.18 per diluted share over the past four quarters, with a net profit margin of -411.9%.
Looking at the long-term picture, RNA's historical earnings data spans multiple years. The company achieved its highest annual net income of -$12M in fiscal 2018.
Atrium Therapeutics, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including SRPT ($65M net income, -32.5% margin), MDWD (-$26M net income, -140.8% margin), FOLD (-$27M net income, -4.3% margin), RNA has room to improve margins relative to the peer group. Compare RNA vs SRPT →
RNA Earnings vs Peers
Earnings metrics vs comparable public companies
RNA Historical Earnings Data (2018–2025)
8 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$77M | +76.2% | -$77M | $-4.48 | -411.9% | -412.6% |
| 2024 | -$322M | -51.9% | -$379M | $-2.89 | -2957.7% | -3477.4% |
| 2023 | -$212M | -22.0% | -$236M | $-2.91 | -2219.9% | -2464.4% |
| 2022 | -$174M | -47.4% | -$179M | $-3.34 | -1886.3% | -1939.6% |
| 2021 | -$118M | -166.1% | -$118M | $-2.85 | -1265.4% | -1265.8% |
| 2020 | -$44M | -79.3% | -$44M | $-2.05 | -653.5% | -652.4% |
| 2019 | -$25M | -107.3% | -$17M | $-0.86 | -1066.6% | -747.4% |
| 2018 | -$12M | - | -$10M | $-0.58 | -3148.8% | -2769.9% |
Download Data
Export RNA earnings history in CSV or JSON format
Free sign-in required to download data
What if you invested $1,000 in RNA back in 2018?
Total return with dividends reinvested · 8+ years of data
Calculate ReturnsHow much would $100/month in RNA be worth today?
Dollar cost averaging vs lump sum · see how regular investing compounds over time
Run the NumbersIs RNA Undervalued Right Now?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationRNA vs LLY — which is the better buy?
Side-by-side revenue, margins, P/E and 10-year returns vs Eli Lilly and Company.
Compare NowRNA — Frequently Asked Questions
Quick answers to the most common questions about buying RNA stock.
What is RNA earnings per share (EPS)?
RNA trailing twelve-month (TTM) diluted EPS is $-23.18, reflecting -55.0% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2018 to 2025 is available in the table on this page.
What is Atrium Therapeutics, Inc.'s net income?
Atrium Therapeutics, Inc. (RNA) trailing twelve-month net income is $-396M as of 2025. Earnings declined -55.0% year-over-year.
Is RNA profitable?
RNA is not currently profitable on a TTM basis, reporting a net loss of $-396M. Net margin is -411.9%. Investors should monitor for a return to profitability.
What is RNA's earnings growth rate?
RNA compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2018 to 2025.
What are RNA's profit margins?
Atrium Therapeutics, Inc. net profit margin is -411.9%, operating margin is -412.6%, and gross margin is +100.0%. Below-average margins reflect competitive or cost pressures. Return on Equity is -9.4%.
Is RNA growing earnings?
RNA earnings are declining — EPS fell -55.0% year-over-year. TTM net income dropped to $-396M. This contrasts with the 5-year CAGR of N/A.
What was RNA's best earnings year?
Atrium Therapeutics, Inc.'s highest annual net income on record is $-12M, achieved in fiscal year 2018. Earnings history on this page spans 2018 to 2025 and includes all annual and quarterly figures.
What were RNA's earnings last quarter?
RNA's most recent reported quarter was Q1 2026. Net income was $-17M with diluted EPS of $-0.97. For a full breakdown of all quarters, see the quarterly earnings table on this page.